Immunocore Holdings plc Operating Cash Flow
Immunocore Holdings plc (IMCR) reported Operating Cash Flow of $2.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Immunocore Holdings plc net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $15.93M, a 38.65% decline year-over-year.
- Immunocore Holdings plc net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$13.78M, a 3266.67% decline year-over-year.
- Immunocore Holdings plc net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$32.66M.
- Immunocore Holdings plc net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.46M, a 121.09% decline year-over-year.
- Immunocore Holdings plc net cash provided by (used in) operating activities for fiscal 2025 was -$10.71M, a 141.10% decline from fiscal 2024.
- Immunocore Holdings plc net cash provided by (used in) operating activities for fiscal 2024 was $26.06M, a 786.43% increase from fiscal 2023.
- Immunocore Holdings plc net cash provided by (used in) operating activities for fiscal 2023 was $2.94M.
- Immunocore Holdings plc net cash provided by (used in) operating activities for fiscal 2022 was -$49.21M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.15M 10-Q · filed 2026-08-06 | -$30.50M derived: sum of 3 quarters · filed 2026-08-06 | -$34.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$13.78M 10-Q · filed 2026-05-06 | -$46.43M derived: sum of 2 quarters · filed 2026-05-06 | -$50.89M derived: sum of 3 quarters · filed 2026-05-06 | -$24.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$32.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$37.11M derived: sum of 2 quarters · filed 2026-02-25 | -$11.15M derived: sum of 3 quarters · filed 2026-08-06 | -$10.71M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$4.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $21.51M derived: sum of 2 quarters · filed 2026-08-06 | $21.94M 10-Q · filed 2025-11-06 | $7.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $25.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $26.40M 10-Q · filed 2026-08-06 | $12.45M derived: sum of 3 quarters · filed 2026-08-06 | $33.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $435.00K 10-Q · filed 2026-05-06 | -$13.52M derived: sum of 2 quarters · filed 2026-05-06 | $7.61M derived: sum of 3 quarters · filed 2026-05-06 | $31.08M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$13.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.18M derived: sum of 2 quarters · filed 2026-02-25 | $30.65M derived: sum of 3 quarters · filed 2026-02-25 | $26.06M 10-K · filed 2026-02-25 |
| 2024-09-30 | $21.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $44.60M derived: sum of 2 quarters · filed 2025-11-06 | $40.01M 10-Q · filed 2025-11-06 | $22.28M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $23.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $18.89M 10-Q · filed 2025-08-07 | $1.15M derived: sum of 3 quarters · filed 2026-02-25 | $11.24M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$4.59M 10-Q · filed 2025-05-07 | -$22.32M derived: sum of 2 quarters · filed 2026-02-25 | -$12.23M derived: sum of 3 quarters · filed 2026-02-25 | -$12.19M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$17.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$7.64M derived: sum of 2 quarters · filed 2026-02-25 | -$7.60M derived: sum of 3 quarters · filed 2026-02-25 | $2.94M 10-K · filed 2026-02-25 |
| 2023-09-30 | $10.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $10.13M derived: sum of 2 quarters · filed 2024-11-06 | $20.67M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $10.58M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $10.54M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$49.21M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$143.11M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |